Clinical trial
Safety and Efficacy of Zemplar Capsule in Reducing Serum iPTH Levels in Chronic…
NCT00048516 · Abbott, Industry · Completed
Key facts
| NCT number | NCT00048516 |
|---|---|
| Title | Safety and Efficacy of Zemplar Capsule in Reducing Serum iPTH Levels in Chronic Kidney Disease Subjects (Daily Dosing) |
| Official title | Safety and Efficacy of Zemplar Capsule in Reducing Serum iPTH Levels in Chronic Kidney Disease Subjects (Daily Dosing) |
| Lead sponsor | Abbott, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Renal Insufficiency, Chronic |
| Intervention type | Drug |
| Interventions | paricalcitol capsule |
| Enrollment | 68 |
| Start date | Feb 1, 2002 |
| First posted | Nov 4, 2002 |
| Last update posted | Aug 2, 2006 |
| Countries | Poland, United States |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: